|
|
22. Kongress der DGII 2008
Abstracts DGII 2008
R93
Astigmatism Management in Cataract
Surgery with the Acrysof Toric
Intraocular
Lens (IOL)
Nuijts RMMA
Maastricht (Niederlande)
Purpose: To present clinical data on residual refractive astigmatism,
uncorrected visual acuity (UCVA), and rotational misalignment of
the Acrysof Toric IOL (SN60TT) after implantation in cataract surgery.
Setting/venue: Department of Ophthalmology, Academic Hospital
Maastricht. Methods: The AcrySof Toric IOL contains a toric
component on the posterior surface of the optic, but is otherwise
structurally identical to the AcrySof single-piece IOL. Three toric
models were evaluated in cylinder powers of 1.50D (SN60T3,
n = 13), 2.25D (SN60T4, n = 10), and 3.0D (SN60T5, n = 11) at the IOL
plane. An Acrysof Toric T3 – 5 IOL was implanted in 47 eyes of 18
patients with a mean age of 73.0 ± 15.5. The average pre-op refractive
and corneal cylinder was - 2.96 ± 1.74 and 2.91 ± 1.95 respectively.
In 13 eyes the preoperative corneal astigmatism exceeded
the SN60T5 toric IOL power and a partial astigmatism correction
was intended. Outcome measures included residual refractive astigmatism,
uncorrected visual acuity and IOL misalignment. Results: At
6 months postoperatively, the average refractive cylinder was
0.69D ± 0.46, - 0.43D ± 0.43 and - 0.75D ± 0.45 in T3, T4 and T5
groups, respectively. The average UCVA for the T3 – 5 groups was
0.79 ± 0.24, 0.96 ± 0.19 and 0.83 ± 0.16. The IOL misalignment for
T3 – 5 groups was 2.6 +/-, 4.14+/- and 4.86+/- degrees, respectively.
UCVA of 0.8 or better was achieved in 81% of all eyes in T3 – 5
groups. In the 13 eyes where partial astigmatism correction was
intended an UCVA of 0.5 or better was achieved in 73% of eyes and
53% of patients were spectacle independent for reading due to residual
mixed astigmatism. Conclusion: Astigmatism correction in
cataract surgery with the Acrysof Toric IOL is effective and safe. In
cases with partial astigmatism correction residual mixed astigmatism
may result in spectacle freedom for near vison. Financial disclosure:
none.
Erschienen in: Klin Monatsbl Augenheilkd 2008; 225: Suppl 1, S1–S24 |
22.html